Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership2,185,329 shares
Latest Disclosed Value $ 6,708,961
Morgan Stanley reports 61.37% decrease in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 2,185,329 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $6,708,961 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 5,657,578 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of -61.37% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,185,329 -3,472,249 -61.37 6,709 -71.01 0.0004
2026-05-27 2025-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 5,657,578 -1,632,775 -22.40 23,140 -34.96 0.0014
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 5,657,578 -1,632,775 23,140 0.0014
2026-05-27 2025-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 7,290,353 1,600,741 28.13 35,577 23.57 0.0022
2025-11-14 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 7,290,353 1,600,741 35,577 0.0022
2025-08-15 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 5,689,612 679,179 13.56 28,789 8.62 0.0019
2025-05-15 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 5,010,433 2,149,906 75.16 26,505 37.07 0.0019
2025-05-15 2024-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 2,860,527 983,326 52.38 19,337 56.32 0.0014
2025-02-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,860,527 983,326 19,337 0.0014
2025-05-14 2024-09-30 13F/A-2 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,877,201 108,889 6.16 12,371 -6.73 0.0009
2025-02-14 2024-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,877,201 108,889 12,371 0.0009
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,877,201 108,889 12,371 0.0009
2025-05-14 2024-06-30 13F/A-2 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,768,312 -195,465 -9.95 13,262 -32.26 0.0010
2024-10-17 2024-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,768,312 -195,465 13,262 0.0010
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,768,312 -195,465 13,262 0.0010
2024-10-17 2024-03-31 13F/A-2 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,963,777 -612,122 -23.76 19,579 -22.92 0.0016
2024-08-16 2024-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,963,777 -612,122 19,579 0.0002
2024-05-15 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,963,777 -612,122 19,579 0.0016
2024-08-16 2023-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 2,575,899 1,769,277 219.34 25,398 311.64 0.0022
2024-02-13 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,575,899 1,769,277 25,398 0.0022
2023-11-15 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 806,622 416,393 106.70 6,171 111.66 0.0006
2023-08-14 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 390,229 130,862 50.45 2,915 68.59 0.0003
2023-05-15 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 259,367 -73,804 -22.15 1,730 -32.67 0.0002
2023-02-14 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 333,171 57,229 20.74 2,569 -12.56 0.0003
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 275,942 54,238 24.46 2,937 62.71 0.0004
2022-10-27 2022-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 221,704 81,107 57.69 1,805 79.25 0.0002
2022-08-15 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 221,704 81,107 1,805 0.0000
2022-10-27 2022-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 140,597 25,096 21.73 1,007 -49.09 0.0001
2022-05-13 2022-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 140,597 25,096 1,007 0.0001
2022-02-14 2021-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 115,501 105,801 1,090.73 1,978 787.00 0.0002
2021-11-15 2021-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 9,700 8,564 753.87 223 443.90 0.0000
2021-08-23 2021-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN CL A 75629V104 1,136 1,136 41 0.0000
2021-08-16 2021-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,136 1,136 41 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.